The Royal Marsden launches world’s first fully integrated multiple myeloma patient pathway

The Royal Marsden launches world’s first fully integrated multiple myeloma patient pathway

• First-of-its-kind fully integrated multiple myeloma patient pathway combines advanced diagnostics with clinical expertise
• Enables more personalised, evidence-based treatment decisions, including identifying patients suitable for treatment breaks.
• Creates opportunities to safely de-escalate or even pause treatment for some patients.   

The Royal Marsden today announces the launch of MyTrack™ Myeloma, the world’s first fully integrated patient pathway for multiple myeloma. This innovative, patient-centred approach brings together leading-edge innovation in advanced diagnostics and clinical expertise to transform how multiple myeloma is understood, monitored, managed and treated, with the goal of significantly improving the patient experience. The MyTrack Myeloma pathway is initially available to private patients, with Bupa the first health insurer to cover the treatment for its customers with cancer cover. The Royal Marsden’s ambition Is to work with the NHS to bring this pioneering pathway to more patients in the future.  Multiple myeloma is an incurable cancer of the plasma cells, with around 6,000 people diagnosed every year in the UK. Outcomes for patients with multiple myeloma have improved significantly in recent years due to advances in drug therapies, however, despite being treatable, multiple myeloma remains incurable with patients requiring ongoing maintenance therapy. Current treatments are typically continuous and lifelong and may not always reflect the individual biology of a patient’s disease. Technical Lead for Biochemistry at The Royal Marsden with the with EXENT analsyer   Patient communities worldwide have consistently highlighted the importance of more personalised approaches to care - including the possibility of treatment breaks, which can improve quality of life and reduce side effects from ongoing therapy. However, standard diagnostic tools do not always provide sufficient insight into the cancer’s behaviour, such as aggressiveness, likelihood of relapse, or suitability for treatment pauses. As multiple myeloma varies widely between patients, identifying those who may safely benefit from treatment breaks requires precise tumour profiling and highly sensitive monitoring. MyTrack Myeloma addresses this gap by integrating advanced diagnostic technologies into a single, coordinated pathway.  Professor Martin Kaiser, Consultant Haematologist at The Royal Marsden NHS Foundation Trust and Professor in Molecular Haematology at The Institute of Cancer Research, London said: “Patients with multiple myeloma can remain on treatment for more than ten years. By incorporating advanced diagnostic tools, clinicians can gain a much clearer understanding of a patient’s cancer from the outset, enabling more personalised and effective first-line treatment, ensuring patients receive the right treatment at the right time These tools can also support more precise monitoring, creating opportunities to de-escalate or even pause treatment safely for some  patients.” Dr Tim Woodman, Medical Director for Cancer Services at Bupa Insurance said: “Multiple myeloma is a complex, lifelong cancer where treatment decisions need to evolve alongside the disease. What’s so powerful about this pathway is the depth of insight it provides, helping clinicians and patients make more informed, personalised decisions throughout care. We’re proud to be bringing this innovative approach to Bupa health insurance customers first, giving people earlier access to world‑leading diagnostics that can support better outcomes, improve quality of life, and avoid unnecessary treatment where it’s safe to do so.” MyTrack Myeloma has been developed by internationally renowned haematology experts at The Royal Marsden. The pathway brings together state-of-the-art diagnostic technologies into a single, integrated model, delivering a deeper understanding of each patient’s disease from the outset. Clinicians receive a clear, integrated report prepared by a myeloma specialist, combining tumour profiling with minimal residual disease monitoring.  When interpreted alongside full-body MRI imaging, carried out by the patient's local clinician, these insights enable confident, shared decision-making.  In the MyTrack Myeloma pathway there are three advanced diagnostic tests that complement existing standards of care:

•  SKY92 (SkylineDx) - a gene expression test that enhances tumour progression risk classification and improves the precision of baseline characterisation, helping guide treatment intensity and duration from the outset.
• clonoSEQ® (Adaptive Biotechnologies) - a highly sensitive next-generation sequencing (NGS)-based test used to detect, quantify, and track measurable residual disease (MRD) over time. With sufficient input material, it can detect as little as one cancer cell among a million healthy cells. Longitudinal tracking of residual disease provides clinicians and patients with lymphoid cancer insights into treatment response and disease dynamics, which can help inform individualised treatment decisions , including treatment de‑escalation.
•   EXENT® System (The Binding Site) —an analyser that uses  minimally invasive, blood-based tests to enable ongoing monitoring and early detection of disease reactivation, making it particularly suitable for long-term follow-up and use during treatment breaks. The EXENT System test is primarily being used for research and is also available for NHS patients in a highly limited capacity.    

Together, these technologies provide a comprehensive and personalised view of disease biology and response over time. The MyTrack Myeloma pathway is designed to be flexible, allowing patients to enter at different stages of their care. Local physicians and care teams determine the most appropriate entry point, supported by specialist input from The Royal Marsden team where needed. This ensures care remains tailored to individual patient needs while maintaining consistency in diagnostic quality and interpretation. The MyTrack Myeloma diagnostic pathway and associated tests will be available from early summer 2026. For further information, including pricing details and how to request tests, please contact ClinicalGenomics_PP@rmh.nhs.uk or visit royalmarsden.nhs.uk/MyTrackMyeloma